Susan Margaret Bright
Boehringer Ingelheim
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Susan Margaret Bright.
Human antibodies | 1994
John Robert Adair; Diljeet Singh Athwal; Mark William Bodmer; Susan Margaret Bright; Alexander M. Collins; Virginia L. Pulito; Patricia E. Rao; Roweena Reedman; Annette L. Rothermel; Danlin Xu; Robert A. Zivin; Linda Jolliffe
OKT3 is a murine monoclonal antibody which recognizes an epitope on the epsilon-subunit within the human CD3 complex. OKT3 possesses potent immunosuppressive properties in vivo and has been proven effective in the treatment of renal, heart and liver allograft rejection. Despite its efficacy, significant problems remain associated with OKT3 therapy, i.e. T-cell activation and the anti-murine antibody response. To address the problem of the anti-murine antibody response we have constructed humanized versions of OKT3. One of the humanized derivatives, gOKT3-7 incorporating the OKT3 complementarity determining regions plus a small number of alterations to the human framework, has an affinity of 1.4 x 10(9) M-1 compared with 1.2 x 10(9) M-1 for the murine OKT3. A humanized antibody (gOKT3-1) incorporating only the CDRs from OKT3 was found to be functionally inactive, confirming the requirement for nonCDR substitutions. gOKT3-7 retains the ability of mOKT3 to induce T cell proliferation in vitro and appears to be a good candidate for further development for in vivo therapy.
Expert Opinion on Investigational Drugs | 1995
John Robert Adair; Susan Margaret Bright
(1995). Monthly Update: Biologicals & Immunologicals: Progress with humanised antibodies - An update. Expert Opinion on Investigational Drugs: Vol. 4, No. 9, pp. 863-870.
Immunology Today | 1991
Susan Margaret Bright; John Robert Adair; David Secher
Access to a wide range of high quality and increasingly sophisticated reagents and equipment has underpinned the great surge of knowledge in basic immunology and the growing interest in clinical immunointervention. In this article, the first in an occasional series on immunological research and development in industry, Sue Bright and colleagues outline the key steps in a development programme to take a humanized monoclonal antibody into the clinic. The procedures involved in developing such reagents, particularly for clinical use, are long and require considerable ingenuity and scientific creativity.
Archive | 1991
John Robert Adair; Martyn Kim Robinson; Susan Margaret Bright; Robert Rothlein
Archive | 1992
John Robert Adair; Martyn Kim Robinson; Susan Margaret Bright; Robert Rothlein
Archive | 1991
John Robert Adair; Martyn Kim Robinson; Susan Margaret Bright; Robert Rothlein; Robert George Road Stoken John; Kim Strawberry Vale Rob Martyn; Margaret Bright Susan; A Rothlein Robert
Archive | 1991
John Robert Adair; Martyn Kim Robinson; Susan Margaret Bright; Robert Rothlein
Archive | 1991
John Robert Adair; Martyn Kim Robinson; Susan Margaret Bright; Robert Rothlein
Archive | 1991
John Robert Adair; Martyn Kim Robinson; Susan Margaret Bright; Robert Rothlein
Archive | 1991
John Robert Adair; Martyn Kim Robinson; Susan Margaret Bright; Robert Rothlein